Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK2302024A in WT1-positive Primary Invasive Breast Cancer
NCT01220128Phase 2Terminated
- Sponsor
- GSK
- Start
- Apr 2011
- Primary completion
- Nov 2014
- Modality
- Therapeutic Vaccines, Recombinant Protein Vaccines, Peptides
- Countries
- 7
01
Overview
A Phase 2 trial of GSK2302024A in breast cancer, sponsored by GSK. Started Apr 2011; status: terminated.
02
Drugs
GSK2302024A
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01220128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220128.